Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

21.77 -8.86 (-28.93%)
Streaming Delayed Price Updated: 1:11 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Let's take a look at the stocks that are in motion in today's session.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Crude Oil Gains 2%; ABM Industries Shares Plunge After Q2 Results
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 500 Points; Nonfarm Payrolls Top Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Discover the top movers in Friday's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Lululemon Cuts Earnings Forecast, Joins DocuSign, Samsara And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Rent the Runway Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40
The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated. 
Via Stocktwits
Exposures Product Safety
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
From Vera Therapeutics
Via GlobeNewswire
Here are the top movers in Monday's session.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Which stocks are gapping on Monday?
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data
Vera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phase 3 trial data. 
Via Benzinga
These stocks that are showing activity before the opening bell on Monday.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing. 
Via Benzinga
Exposures Product Safety
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.